+ Follow OBESE SUBJECTS Tag
Array
(
[results] => Array
(
[0] => Array
(
[ArticleID] => 251586
[Title] => Reducing diabetes risk
[Summary] => Treatment of type 2 diabetes has recently acquired a new development as the European Commission (EC) recently approved the use of the weight loss medication, orlistat, in managing and reducing the risk for developing type 2 diabetes.
Its efficacy in reducing the risk of developing type 2 diabetes is backed by the landmark XENDOS (Xenical in the prevention of Diabetes in Obese Subjects) study, which showed for the first time that a fat blocker medication can significantly lessen the risk of developing type 2 diabetes.
[DatePublished] => 2004-05-27 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
[1] => Array
(
[ArticleID] => 243910
[Title] => PREVENTING ‘SYNDROME X’
[Summary] => In recent years, a sinister-sounding condition called "Syndrome X" has circulated in the scientific and medical field. It has been linked to the progression of several potentially deadly diseases.
Syndrome X is a term for a cluster of conditions that tend to appear together in some individuals. Hypertension, high triglyceride, high cholesterol, diabetes, obesity and coronary artery disease make up the cluster of conditions that define Syndrome X.
[DatePublished] => 2004-03-25 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
)
)
OBESE SUBJECTS
Array
(
[results] => Array
(
[0] => Array
(
[ArticleID] => 251586
[Title] => Reducing diabetes risk
[Summary] => Treatment of type 2 diabetes has recently acquired a new development as the European Commission (EC) recently approved the use of the weight loss medication, orlistat, in managing and reducing the risk for developing type 2 diabetes.
Its efficacy in reducing the risk of developing type 2 diabetes is backed by the landmark XENDOS (Xenical in the prevention of Diabetes in Obese Subjects) study, which showed for the first time that a fat blocker medication can significantly lessen the risk of developing type 2 diabetes.
[DatePublished] => 2004-05-27 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
[1] => Array
(
[ArticleID] => 243910
[Title] => PREVENTING ‘SYNDROME X’
[Summary] => In recent years, a sinister-sounding condition called "Syndrome X" has circulated in the scientific and medical field. It has been linked to the progression of several potentially deadly diseases.
Syndrome X is a term for a cluster of conditions that tend to appear together in some individuals. Hypertension, high triglyceride, high cholesterol, diabetes, obesity and coronary artery disease make up the cluster of conditions that define Syndrome X.
[DatePublished] => 2004-03-25 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
)
)
abtest
